One Study Down, Three To Go On Animas’ First-Gen Artificial Pancreas Project
This article was originally published in The Gray Sheet
Following a successful feasibility study, the J&J unit still has multiple clinical milestones to hit before it can put its closed-loop diabetes treatment system up for market approval.
You may also be interested in...
Recent data and study announcements in cardiac, neuro and diabetes.
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.
Artificial pancreas feasibility, computed tomography cancer risk documentation and more data updates.